Vilsbøll, Tina

The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 44

The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

Dalsgaard, N. B., Gasbjerg, L. S., Hansen, L. S., Hansen, N. L., Stensen, S., Hartmann, B., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · European Journal of Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

GIP’s involvement in the pathophysiology of type 2 diabetes

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer

Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety

Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Cited by 31

Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control subjects

Bagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 27

Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic

Hansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 23

Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes

Vilsbøll, T., Lindahl, C. Ø., Nielsen, N. F., & Tikkanen, C. K. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 22

Cardiovascular biomarkers in clinical studies of type 2 diabetes

Baldassarre, M. P. A., Andersen, A., Consoli, A., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes, Obesity and Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 22

Glucose‐dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double‐blind, placebo‐controlled, crossover clinical trial

Heimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13

Higher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion

Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 12